Vaxart's GAAP net income for 3 months of 2022 was $25.101 million, up 56.8% from $16.007 million in the previous year. Revenue decreased 5.95 times to $85,000 from $506,000 a year earlier.

Vaxart's GAAP loss for 2021 was $70.47 million, up 2.2 times from $32.22 million in the previous year. Revenue decreased 4.5 times to $0.892 million from $4.046 million a year earlier.

Vaxart has purchased equipment and sublet KindredBio's manufacturing facilities in Burlingame, California. The company will use them to manufacture materials for Vaxart's COVID-19 vaccine tablets. Vaxart plans to begin operating the facility in Q1 2022.

Vaxart's GAAP loss for 9M 2021 was $49.706 mln, up 2.7 times from $18.359 mln in the previous year. Revenue decreased 4.5 times to $0.818 million from $3.69 million a year earlier.